Abiopharma

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2025 CIRSE Annual Congress

FDA approve FUROSEMIDE

FDA approve PHYTONADIONE

NASDAQ symbol attribute type Security_Name was changed. Previous value: Renovaro Inc. - Common Stock. New value: Lunai Bioworks Inc. - Common Stock.

Shareholder Alert: The Ademi Firm investigates whether Tourmaline Bio, Inc. is obtaining a Fair Price for its Public Shareholders

Best Cheap Air Fryers for Healthy Cooking in 2025

Best Budget Cheap Gaming Mouse Options

Best Budget Mirrorless Cameras for Photography Beginners (2025)

Best Budget Soundbars for Enhanced Home Audio (2025)

Best Budget Wireless Headphones

Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)

CAPR INVESTOR ALERT: Kirby McInerney LLP Notifies Capricor Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit

New Form 3 - Vor Biopharma Inc. Filed: 2025-09-08 AccNo: 0001415889-25-023931 Size: 8 KB